Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 10;10(1):165–186. doi: 10.1007/s40121-020-00384-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Fig. 1 — Algorithm for choosing PrEP. ACEi angiotensin-converting enzyme inhibitor, AE adverse event, ARB angiotensin receptor blocker, BMI body mass index, CKD chronic kidney disease, CVD cardiovascular disease, F/TAF emtricitabine/tenofovir alafenamide, F/TDF emtricitabine/tenofovir disoproxil fumarate, MSM men who have sex with men, NSAID non-steroidal anti-inflammatory drug, PrEP pre-exposure prophylaxis. ^aIf no significant drug–drug interactions. ^bEligibility is limited to MSM who have infrequent sex, are able to plan for sex at least 2 h in advance, and do not have chronic hepatitis B infection. ^cF/TDF is currently not approved for on-demand dosing. ^dIncluding psychotropic medications, NSAIDs, ACEi/ARBs, certain antibiotics, certain chemotherapies.^eIncluding corticosteroids. ^fWeight gain has been observed among individuals using both F/TAF and F/TDF, with slightly less weight gain among those on F/TDF, which may be a factor to consider when discussing PrEP options